Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789242 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
A Phase 1 study, sponsored by Criterium.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01789242 is a Phase 1 study that has completed, run by Criterium. The registered enrollment target is 32 participants.
The verdict
NCT01789242, a Phase 1 study, has completed, sponsored by Criterium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789242
The ClinicalTrials.gov registry entry for NCT01789242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01789242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789242 about?
NCT01789242 is a clinical study titled "A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis". This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
What is the current status of trial NCT01789242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01789242?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01789242?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.